CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix.
Formulation
Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*
Host
Mouse
Immunogen Region
Human colon carcinoma extract was used as the immunogen for the anti-CEA antibody.
Isotype
Mouse IgG1, kappa
Species Reactivity
Human
Note
Optimal dilution of the anti-CEA antibody to be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Uniprot
P06731
Format
Purified
Purity
Protein G affinity chromatography
Storage
Store the anti-CEA antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Applications
IHC-P
Description
The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.